0 rating

Miscellaneous

de Gramont A, Hubbard J, Shi Q et al.

Hôpital Saint Antoine, Paris, France.

 J Clin Oncol 2010;28:460–5.

Editor’s note: In this study, de Gramont et al. examined the relationship between disease-free survival (DFS) and overall survival (OS) in the ACCENT (Adjuvant Colon Cancer Endpoints) patient dataset. The aim was to confirm or refute a finding of the MOSAIC (Multicenter International Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin [FOLFOX] in the Adjuvant Treatment of Colorectal Cancer) study, in which the investigators found that the OS benefit of FOLFOX chemotherapy was not manifest until 6 years, even though a DFS benefit was found at 3 years.

Return to top
This journal is supported by an educational grant from

LATEST ARTICLES

Our most popular articles